|
1
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: Moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Itoh K, Yamada A, Mine T and Noguchi M:
Recent advances in cancer vaccines: An overview. Jpn J Clin Oncol.
39:73–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mine T, Sato Y, Noguchi M, Sasatomi T,
Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, et
al: Humoral responses to peptides correlate with overall survival
in advanced cancer patients vaccinated with peptides based on
pre-existing, peptide-specific cellular responses. Clin Cancer Res.
10:929–937. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ullenhag GJ, Frödin JE, Strigård K,
Mellstedt H and Magnusson CG: Induction of IgG subclass responses
in colorectal carcinoma patients vaccinated with recombinant
carcinoembryonic antigen. Cancer Res. 62:1364–1369. 2002.PubMed/NCBI
|
|
5
|
Aoki M, Ueda S, Nishikawa H, Kitano S,
HIrayama M, Ikeda H, Toyoda H, Tanaka K, Kanai M, Takabayashi A, et
al: Antibody responses against NY-ESO-1 and HER2 antigens in
patients vaccinated with combinations of cholesteryl pullulan
(CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine. 27:6854–6861.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kageyama S, Kitano S, Hirayama M, Nagata
Y, Imai H, Shiraishi T, Akiyoshi K, Scott AM, Murphy R, Hoffman EW,
et al: Humoral immune responses in patients vaccinated with 1–146
HER2 protein complexed with cholesteryl pullulan nanogel. Cancer
Sci. 99:601–607. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karagiannis P, Gilbert AE, Josephs DH, Ali
N, Dodev T, Saul L, Correa I, Roberts L, Beddowes E, Koers A, et
al: IgG4 subclass antibodies impair antitumor immunity in melanoma.
J Clin Invest. 123:1457–1474. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Plaen E, Naerhuyzen B, De Smet C,
Szikora JP and Boon T: Alternative promoters of gene MAGE4a.
Genomics. 40:305–313. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ
and Chen YT: Cancer/testis antigens: An expanding family of targets
for cancer immunotherapy. Immuno Rev. 188:22–32. 2002. View Article : Google Scholar
|
|
10
|
Resnick MB, Sabo E, Kondratev S, Kerner H,
Spagnoli GC and Yakirevich E: Cancer-testis antigen expression in
uterine malignancies with an emphasis on carcinosarcomas and
papillary serous carcinomas. Int J Cancer. 101:190–195. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yakirevich E, Sabo E, Lavie O, Mazareb S,
Spagnoli GC and Resnick MB: Expression of the MAGE-A4 and NY-ESO-1
cancer-testis antigens in serous ovarian neoplasms. Clin Can Res.
9:6453–6460. 2003.
|
|
12
|
Tajima K, Obata Y, Tamaki H, Tamaki H,
Yoshida M, Chen YT, Scanlan MJ, Old LJ, Kuwano H, Takahashi T, et
al: Expression of cancer/testis (CT) antigens in lung cancer. Lung
Cancer. 42:23–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prasad ML, Jungbluth AA, Petal SG, Iversen
K, Hoshaw-Woodard S and Busam KJ: Expression and significance of
cancer/testis antigens in primary mucosal melanoma of the head and
neck. Head Neck. 26:1053–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang
Y and Gu J: Expression profile of cancer-testis genes in 121 human
colorectal cancer tissue and adjacent normal tissue. Clin Can Res.
11:1809–1814. 2005. View Article : Google Scholar
|
|
15
|
Gure AO, Chua R, Williamson B, Gonen M,
Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ and
Altorki NK: Cancer-testis genes are coordinately expressed and are
markers of poor outcome in non-small cell lung cancer. Clin Can
Res. 11:8055–8062. 2005. View Article : Google Scholar
|
|
16
|
Peng JR, Chen HS, Mou DC, Cao J, Cong X,
Qin LL, Wei L, Leng XS, Wang Y and Chen WF: Expression of
cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and
its correlation with clinical parameters. Cancer Lett. 219:223–232.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barrow C, Browning J, MacGregor D, Davis
ID, Sturrock S, Jungbluth AA and Cebon J: Tumor antigen expression
in melanoma varies according to antigen and stage. Clin Can Res.
12:764–771. 2006. View Article : Google Scholar
|
|
18
|
Akcakanat A, Kanda T, Tanabe T, Komukai S,
Yajima K, Nakagawa S, Ohashi M and Hatakeyama K: Heterogeneous
expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal
cancer: Implications for immunotherapy. Int J Cancer. 118:123–128.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kageyama S, Wada H, Muro K, Niwa Y, Ueda
S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, et al:
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with
cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and
survival benefits of esophageal cancer patients. J Transl Med.
11:2462013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gu XG, Schmitt M, Hiasa A, Nagata Y, Ikeda
H, Sasaki Y, Akiyoshi K, Sunamoto J, Nakamura H, Kuribayashi K and
Shiku H: A novel hydrophobized polysaccharide/oncoprotein complex
vaccine induces in vitro and in vivo cellular and
humoral immune responses against HER2-expressing murine sarcomas.
Cancer Res. 58:3385–3390. 1998.PubMed/NCBI
|
|
21
|
Okamoto M, Furuichi S, Nishioka Y,
Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y,
et al: Expression of toll-like receptor 4 on dendritic cells is
significant for anticancer effect of dendritic cell-based
immunotherapy in combination with an active component of OK-432, a
streptococcal preparation. Cancer Res. 64:5461–5470. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakahara S, Tsunoda T, Baba T, Asabe S and
Tahara H: Dendritic cells stimulated with a bacterial product,
OK-432, efficiently induce cytotoxic T lymphocytes specific to
tumor rejection peptide. Cancer Res. 63:4112–4118. 2003.PubMed/NCBI
|
|
23
|
No authors listed, . Japanese translation
of common terminology criteria for adverse events (CTCAE), and
instructions and guidelines. Int J Clin Oncol. 9:(Suppl 3). 1–82.
2004.(In Japanese).
|
|
24
|
Wolchok JD, Hoos A, O'Day S, Weber JS,
Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al:
Guidelines for the evaluation of immune therapy activity in solid
tumors: Immune-related response criteria. Clin Cancer Res.
15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nigro EA, Brini AT, Soprana E, Ambrosi A,
Dombrowicz D, Siccardi AG and Vangelista L: Antitumor IgE
adjuvanticity: Key role of Fc epsilon RI. J Immunol. 183:4530–4536.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reali E, Greiner JW, Corti A, Gould HJ,
Bottazzoli F, Paganelli G, Schlom J and Siccardi AG: IgEs targeted
on tumor cells: Therapeutic activity and potential in the design of
tumor vaccines. Cancer Res. 61:5517–5522. 2001.PubMed/NCBI
|
|
28
|
Yoshida K, Noguchi M, Mine T, Komatu N,
Yutani S, Ueno T, Yanagimoto H, Kawano K, Itoh K and Yamada A:
Characteristics of severe adverse events after peptide vaccination
for advanced cancer patients: Analysis of 500 cases. Oncol Rep.
25:57–62. 2011.PubMed/NCBI
|
|
29
|
Kidd P: Th1/Th2 balance: The hypothesis,
its limitations, and implications for health and disease. Altern
Med Rev. 8:223–246. 2003.PubMed/NCBI
|
|
30
|
Romagnani S: Th1 and Th2 in human
diseases. Clin Immunol Immunopathol. 80:225–235. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shaw DR, Khazaeli MB and LoBuglio AF:
Mouse/human chimeric antibodies to a tumor-associated antigen:
Biologic activity of the four human IgG subclasses. J Natl Cancer
Inst. 80:1553–1559. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jutel M and Akdis CA: Immunological
mechanisms of allergen-specific immunotherapy. Allergy. 66:725–732.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aalberse RC, Stapel SO, Schuurman J and
Rispens T: Immunoglobulin G4: An odd antibody. Clin Exp Allergy.
39:469–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Riemer AB, Untersmayr E, Knittelfelder R,
Duschl A, Pehamberger H, Zielinski CC, Scheiner O and
Jensen-Jarolim E: Active induction of tumor-specific IgE antibodies
by oral mimotope vaccination. Cancer Res. 67:3406–3411. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamada A, Yano H, Takao Y, Ono T,
Mastumoto T and Itoh K: Nonmutated self-antigen-derived cancer
vaccine peptides elicit an IgE-independent but mast cell-dependent
immediate-type skin reaction without systemic anaphylaxis. J
Immunol. 176:857–863. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohkouchi S, Yamada A, Imai N, Mine T,
Harada K, Shichijo S, Maeda Y, Saijo Y, Nukiwa T and Itoh K:
Non-mutated tumor-rejection antigen peptides elicit type-I allergy
in the majority of healthy individuals. Tissue Antigens.
59:259–272. 2002. View Article : Google Scholar : PubMed/NCBI
|
